### PLENARY LECTURES

1) Gene editing: powerful new tool for nephrology research and therapy  
   **Toni Cathomen**, Freiburg, Germany

2) New paradigms of the kidney - Vascular-Bone axis in CKD  
   **Klaus Olgaard**, Copenhagen, Denmark

3) From the RNA world to the clinic: RNAs as drugs and drug targets  
   **Bruce Sullenger**, Durham, USA

4) Epidemiology of kidney disease  
   **Marcello Tonelli**, Calgary, Canada

### MINI LECTURES

**Oxygen sensing – from physiology to clinical application**  
**Kai-Uwe Eckardt**, Berlin, Germany

**New ideas on the link between salt and hypertension**  
**Friedrich C. Luft**, Berlin, Germany

**Current place of vaptans in the treatment of hyponatremia**  
**Goce Spasovski**, Skopje, F.Y.R. of Macedonia

**MicroRNAs, mediators and therapeutic targets for renal disease**  
**Laura Denby**, Edinburgh, United Kingdom

**Economics of ADPKD: cost-effectiveness of medical treatment?**  
**Jonathan G. Fox**, Glasgow, United Kingdom

**Role of Wnt signaling in renal fibrosis**  
*Speaker to be confirmed*

**The new standardized classification of glomerulonephritis**  
**Sanjeev Sethi**, Rochester, U.S.A.

**Treatment of C3 glomerulopathy**  
**Yasar Caliskan**, Istanbul, Turkey

**Treatment of complement related glomerulopathies including HUS**  
**Giuseppe Remuzzi**, Bergamo, Italy

**Treatment of HCV in CKD/ESRD: challenges and opportunities**  
**Michel Jadoul**, Brussels, Belgium

**Changing face of HIV related kidney disorders**  
**Alberto Ortiz**, Madrid, Spain

**Liquid kidney biopsy**  
*Yes! We are there*  
**Harald Mischak**, Hannover, Germany  
*No, at least by now*  
**Kerstin Amann**, Erlangen, Germany

**The diagnosis of hematuria in the genetic era: a conundrum solved?**  
**Emmanuelle Plaisier**, Paris, France

**ANCA-associated vasculitis: should it be split into (at least) two diseases?**  
**Benjamin Terrier**, Paris, France

**Biomarkers in IgA nephropathy**  
**Dita Maixnerova**, Prague, Czech Republic

**Frailty in CKD/ESRD**  
**Dimitrios Goumenos**, Patras, Greece

**How to increase serum Klotho concentration?**  
**Makoto Kuro-o**, Shimotsuke, Japan

**FGF23 as a predictor of cardiovascular outcomes in CKD**  
**Martin De Borst**, Groningen, The Netherlands

**Gut-microbiota in immune-mediated inflammatory diseases**  
**Loreto Gesualdo**, Bari, Italy

**Factors affecting adherence in CKD**  
**Anna Birna Almarsdóttir**, Copenhagen, Denmark

**Challenges and opportunities in the conduct of clinical trials in nephrology**  
**Adeera Levin**, Vancouver, Canada

**Inflammation as a driver of premature aging in CKD**  
**Peter Stenvinkel**, Stockholm, Sweden

**Atrial fibrillation in ESRD - what is the best approach to treatment**  
**Adrian Covic**, Iasi, Romania

**Milestones in hyperkalemia therapy or just an innovation**  
**Ziad Massy**, Paris, France

**Aldosterone inhibition in ESRD patients**  
**Patrick Rossignol**, Vandoeuvre-Les-Nancy, France

**Resistant hypertension in ESRD - is it just water that matters?**  
**Francesca Mallamaci**, Reggio Calabria, Italy

**Implementation of new CKD-MBD guidelines**  
**Markus Ketteler**, Coburg, Germany
Neprilsin inhibition in heart failure and CKD - a double-edged sword?
Richard Haynes, Oxford, United Kingdom

Renal anemia of inflammation
Yalcin Solak, Sakarya, Turkey

What can the Danish Nephrology Registry teach us?
James Heaf, Roskilde, Denmark

Impact of transitioning between modalities: the INTEGRATED project
Wim Van Biesen, Ghent, Belgium

Clinical implications of peritoneal transport physiology
Olof Heimbürger, Stockholm, Sweden

New clinical trials on kidney transplantation
Josep Cruzado, Barcelona, Spain

Xenotransplantation - a realistic solution?
Speaker to be confirmed

Criteria to define transplantable kidneys
Giuseppe Grandaliano, Foggia, Italy

How do we treat diabetic patients in stage 4-5 CKD
Speaker to be confirmed

Bariatric surgery and kidney functions
Speaker to be confirmed

The presence and the future of antihypertensive therapy
Giuseppe Mancia, Milan, Italy

AKI in the patient with cirrhosis
Andrew Davenport, London, UK

Staging AKI: from RIFLE to KDIGO to Delta-creatinine?
Norbert H. Lameire, Ghent, Belgium

CI-AKI: are the contrast agents really harmful?
Jolanta Malyszko, Białystok, Poland

Using digital and mobile tools in clinical research
Mitchell R. Lunn, San Francisco, USA

News in the antique concept of Morbus Dominorum: gout as disease of lords
Vincenzo Savina, Messina, Italy

in collaboration with the International Association for the History of Nephrology (IAHN)

SYMPOSIA

SPECIAL AND JOINT SYMPOSIA

Late breaking clinical trials

ERA-EDTA Registry
- Trends in the Kidney Donor Risk Index (KDRI) in Europe
  Maria Pippias, Amsterdam, The Netherlands
- The European EDITH kidney patients survey on treatment modality choice
  Rianne de Jong, Amsterdam, The Netherlands
- Nutritional status in advanced CKD (EQUAL)
  Speaker to be confirmed
- European disparities in access to transplantation and graft failure in children
  Marjolein Bonthuis, Amsterdam, The Netherlands

American Society of Nephrology (ASN) Highlights

ERA-EDTA and Japanese Society of Nephrology (JSN)
Acute/rapidly-progressive nephritic syndrome and vasculitis
- Japanese Renal Biopsy Registry (JRBR)
  Hitoshi Sugiyama, Okayama, Japan
- A nation-wide prospective cohort study in Japanese patients with ANCA-associated vasculitis
  Shinya Kaname, Tokyo, Japan
- Geographical difference – different incidence of glomerular disease or different practice
  Loreto Gesualdo, Bari, Italy
- Complications after renal biopsy – what are the risk factors?
  Bjorn Peters, Skövde, Sweden

ERA-EDTA and Chinese Society of Nephrology (CSN)

ERA-EDTA and European Society of Hypertension (ESH)

ERA-EDTA and European Society for Paediatric Nephrology (ESPN)
Track 1
FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

Renal physiology - tubular transport
- Claudins in the distal nephron
  Speaker to be confirmed
- Tubular handling of calcium and magnesium: Insights from GWAS
  Olivier Devuyst, Zürich, Switzerland
- HNF1beta: roles in the distal nephron
  Stanislas Faguer, Toulouse, France

Mitochondria: critical players in kidney disorders
- Podocyte metabolism in health and disease
  Tobias Huber, Hamburg, Germany
- Mitochondrial cytopathies and the kidney
  Francesco Emma, Rome, Italy
- Mitochondrial dysfunction in AKI
  Ariela Benigni, Bergamo, Italy

APOL1 impact in kidney disease
- Pathogenic roles of lipoproteins and apolipoproteins in kidney diseases
  Arnold Von Eckardstein, Zürich, Switzerland
- The APOL1-associated spectrum of chronic kidney disease
  Barry I. Freedman, Winston-Salem, U.S.A.
  A mouse model of APOL1-associated kidney disease
  Speaker to be confirmed

Track 2
HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

Recent findings in ADPKD
- Utility of prognostic scores in ADPKD
  Emilie Cornec-Le Gall, Brest, France
- Low-osmolar diet and adjusted water intake in ADPKD
  Albert Ong, Sheffield, United Kingdom
- New genes for cystic kidneys and liver
  Peter Harris, Rochester, U.S.A.
- Use of urine peptidome analysis in ADPKD
  Giovambattista Capasso, Naples, Italy

Paediatric nephrology
- Long-term outcome of patients with Lowe syndrome and Dent disease 2
  Detlef Bockenhauer, London, United Kingdom
- Primary disease recurrence - effects on paediatric renal transplantation outcomes
  Speaker to be confirmed
- Methylmalonic aciduria (MMA): new therapeutic perspectives
  Speaker to be confirmed
- Minimal Change Disease
  Marina Vivarelli, Rome, Italy

Pregnancy, CKD and hypertension
- The role of antihypertensive treatment in pregnant women with diabetic nephropathy
  Elisabeth R. Mathiesen, Copenhagen, Denmark
- The role of home blood pressure measurements in pregnancy complicated by hypertension
  Marianne Vestgaard, Copenhagen, Denmark
- Preconception cardiovascular risk factors for gestational hypertension and preeclampsia
  Speaker to be confirmed
- Preeclampsia - does it predict kidney and cardiovascular disease in the future
  Speaker to be confirmed
- Complement activation in kidneys; more than just a signature of IgG deposition
  Cees Van Kooten, Leiden, The Netherlands
Track 3
GLOMERULAR DISEASES AND GENERAL CLINICAL NEPHROLOGY

Membranous nephropathy: the evolving story
- Advances in the pathogenesis of membranous nephropathy
  Pierre Ronco, Paris, France
- Membranous nephropathy and cancer
  Rolf A.K. Stahl, Hamburg, Germany
- New perspectives from recent treatment trials in membranous nephropathy
  Jack F.M. Wetzels, Nijmegen, The Netherlands

IgA nephropathy: from genes to therapeutic controversies
- From genetics to pathophysiology
  Jan Novak, Birmingham, U.S.A.
- Towards pathology-based therapy? Towards a personalized therapy in IgAN
  Rosanna Coppo, Turin, Italy
- From experimental models to new treatment options in humans
  Renato Monteiro, Paris, France

Plasma cell dyscrasias and the kidney
- Myeloma cast nephropathy - any role for extracorporeal treatments?
  Frank Bridoux, Poitiers, France
- Primary amyloidosis - current best practices
  Romana Rysava, Prague, Czech Republic
- Randall-type monoclonal immunoglobulin deposition disease
  Camille Cohen, Paris, France
- MGUS and glomerulonephritis - how to find a causal relationship and how to treat
  Sanjeev Sethi, Rochester, U.S.A.

Rituximab in immune mediated glomerular diseases: one drug does not fit all
- Anti-B cell targeted therapy: anti CD20 and other approaches
  Annette Bruchfeld, Stockholm, Sweden
- Rituximab in idiopathic membranous nephropathy
  Pierre Ronco, Paris, France
- Rituximab in IgA nephropathy
  Fernando Fervenza, Rochester, USA
- Rituximab in ANCA vasculitis
  David Jayne, Cambridge, United Kingdom

Lupus and vasculitis - recent advances in therapy
- Newer agents in the treatment of SLE nephritis
  David Jayne, Cambridge, United Kingdom
- Anti-GBM disease - New subgroups and novel therapies
  Mårten Segelmark, Linköping, Sweden
- IgA Vasculitis in adults: what is it and what should we do about it?
  Alan D. Salama, London, United Kingdom
- Improving survival in ANCA associated vasculitis
  Wladimir M. Szpir, Copenhagen, Denmark

Glomerular diseases in the Omics era
- Large-scale genomic studies: what they have taught us
  Alexander Teumer, Greifswald, Germany
- An integrated view of glomerular pathology
  Tobias Huber, Hamburg, Germany
- Transcontinental Omics studies
  Xueqing Yu, Guangzhou, P.R. China
- Integrative omics approach for comprehensive IgA nephropathy
  Francesco Paolo Schena, Bari, Italy

Track 4
CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

Update in plasmapheresis for treating kidney diseases
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
  Petar Kes, Zagreb, Croatia
- Renal transplantation
  Paolo Malvezzi, Grenoble, France
- Anti-neutrophil cytoplasm antibodies-associated vasculitis
  Charles Pusey, London, United Kingdom
- FSGS - soluble or solid?
  Mario Schiffer, Hannover, Germany

Progression of chronic kidney disease - hot issues beyond blood pressure and renin-angiotensin system
- Can anti-diabetic drugs prevent chronic kidney disease progression?
  Christoph Wanner, Würzburg, Germany
- Interventional antihypertensive therapies and chronic kidney disease - a new window of opportunity?
  Johannes F.E. Mann, Munich, Germany
- Does metabolic acidosis correction prevent chronic kidney disease progression?
  Marcin Adamczak, Katowice, Poland
- Hyperuricemia and chronic kidney disease progression
  Ivan Rychlik, Prague, Czech Republic

New biomarkers of CKD progressions
- A new role for suPAR?
  Jack F.M. Wetzels, Nijmegen, The Netherlands
- Phosphate toxicity and CKD progression
  Markus Ketteler, Coburg, Germany
- Clinical consequences of hypervolemia in CKD patients
  Andrzej J. Wiecz, Katowice, Poland
- Klotho and endocrine FGFs – marker of CKD progression and cardiovascular complications?
  Makoto Kuro-o, Shimotsuke, Japan
Interstitial fibrosis and mechanisms of CKD progression
- New concepts in the pathogenesis of interstitial fibrosis
  Peter Boor, Aachen, Germany
- Are there early biomarkers of interstitial fibrosis?
  Christos Chatziantoniou, Paris, France
- The role of hypoxia in the progression of polycystic kidney disease
  Kai-Uwe Eckardt, Berlin, Germany
- Interstitial fibrosis in kidney transplant recipients
  Marian Klinger, Wroclaw, Poland

Controversy: too much Nephrology?
- The CKD epidemics is overstated
- The CKD epidemics is real and concerning

Focus on surrogate end-points in Nephrology
- Clinical end-points in Nephrology: less simple than it may seem
  Kitty J. Jager, Amsterdam, The Netherlands
- Proteinuria as a clinical end-point in clinical trials in Nephrology: acceptable but not perfect
  Ron T. Gansevoort, Groningen, The Netherlands
- Coronary calcification as a cardiovascular end-point in clinical trials in nephrology: lights and shades
  Gérard London, Fleury-Mérogis, France

CKD as a public health priority: organizational models
- CKD Epidemiology in 2017-2050: primary and secondary prevention
  Marcello Tonelli, Calgary, Canada
- Individualised care for kidney disease without hospital-based clinics?
  Charles Tomson, Bristol, United Kingdom
- Integrated clinical care for CKD
  Adeera Levin, Vancouver, Canada

n-3 PUFA in CKD: does it matter?
- n-3 PUFA and CKD: epidemiological data and follow-up
  Anupam Chandra, Oslo, Norway
- Arrhythmias and sudden cardiac death in dialysis patients: is n-3 PUFA of relevance?
  Jesper Moesgaard Rantanen, Aalborg, Denmark
- n-3 PUFA, inflammation and fibrosis. New insights
  Ivar Anders Eide, Lørenskog, Norway
- n-3 PUFA and interventional studies relevant for the nephrologist
  My Svensson, Lørenskog, Norway

CKD - new therapeutic approaches
- New treatments in diabetic kidney disease
  Peter Rossing, Gentofte, Denmark
- Blood pressure regulation in CKD stage 1-5 (non-dialysis). Achievement of treatment goals and adherence to treatment
  Niels Henrik Buus, Aarhus, Denmark

- Multifactorial risk reduction in CKD - with or without diabetes
  Rikke Borg, Roskilde, Denmark
- The New Nordic Renal Diet
  Louise Salomo, Copenhagen, Denmark

Track 5
END-STAGE RENAL DISEASE, HAEMODIALYSIS

Scheduling dialysis and hemodiafiltration in 2018: a new portfolio?
- Daily and frequent dialysis schedules: rationale, logistics and outcomes
  Nicholas Selby, Derby, United Kingdom
- Incremental dialysis
  Andrew Davenport, London, United Kingdom
- High convective volume in hemodiafiltration: an open question
  Francesco Locatelli, Lecco, Italy

The non-dialysis pathway in ESRD
- Palliative care in ESRD: an overview
  Aine Burns, London, UK
- End-of-life perspectives in haemodialysis
  Stefan H. Jacobson, Stockholm, Sweden
- The non-dialysis pathway: models of care
  Elizabeth Krarup, Herlev, Denmark
- Patient-reported outcome measures in ESRD: relevance for renal palliative care
  Karl-Göran Prütz, Helsingborg, Sweden

Uremic toxicity - New insights
- Uremic toxins and the gut
  Griet Glorieux, Ghent, Belgium
- Uremic toxins and cardiovascular outcomes
  Ziad Massy, Paris, France
- Uremic toxins and the bone in CKD
  Tilman Drueke, Villejuif, France
- Role of inflammation in the uremic phenotype
  Peter Stenvinkel, Stockholm, Sweden

New methods of anaemia management in CKD patients
- PHIs - safety and efficacy - results from recent clinical trials
  David Wheeler, London, United Kingdom
- Iron supplementation in CKD patients – what is the optimal dose and route of administration in 2018?
  Iain C. Macdougall, London, United Kingdom
- Mechanisms of hypertension induced by erythropoietin and related agents
  Speaker to be confirmed
- What is the future of rHuEPO?
  Francesco Locatelli, Lecco, Italy
Neurologic disturbances in CKD
- Acute and chronic cognitive changes in CKD
  David Goldsmith, London, United Kingdom
- Sleep disturbances in ESRD
  Claire Kennedy, Dublin, Ireland
- Headaches during haemodialysis - headaches and treatment
  Speaker to be confirmed

Cardiovascular calcifications in CKD
- Pathophysiology of vascular calcification
  Mario Cozzolino, Milan, Italy
- Vitamin K in CKD patients
  Jürgen Floege, Aachen, Germany
- Calcium sensing receptors
  Jordi Bover, Barcelona, Spain
- Energy-dense diets and vascular calcification
  J. Mariano Rodriguez Portillo, Cordoba, Spain

Treatment of CKD-MBD
- Are all phosphate binders the same for CKD patients?
  João M. Frazão, Porto, Portugal
- Calcimimetics or vitamin D derivatives in ESRD patients?
  John Cunningham, London, United Kingdom
- Osteoporosis in patients with CKD
  Marie-Hélène Lafage-Proust, St. Etienne, France
- Treatment and prevention of fractures in kidney graft recipients
  Rudolf Wüthrich, Zürich, Switzerland

Optimising clinical outcomes and technique survival
- How to reduce technique failure due to peritonitis - the ANZDATA experience
  Speaker to be confirmed
- The role of training in peritonitis prevention - what we have learned from the PEPS Study (Prevention of Peritonitis in Peritoneal Dialysis)
  Susanne Ljungman, Gothenburg, Sweden
- What is the role of assisted PD in the outcomes of frail elderly patients?
  Edwina Brown, London, United Kingdom

Optimising fluid management in PD patients
- Bioimpedance: what have we learned from the IPOD-PD Study
  Wim van Biesen, Ghent, Belgium
- Managing blood pressure in PD patients: what is the optimal balance between bioempedance directed volume status, salt restriction, pharmacological management and sodium removal?
  Olof Heimbürger, Stockholm, Sweden
- What is the role of low sodium solutions?
  Speaker to be confirmed

Home haemodialysis in Europe 2018
- What to do for more frequent use of home haemodialysis in Europe
  Speaker to be confirmed
- Home haemodialysis and control of phosphatemia
  Antonio Bellasi, Milan, Italy
- Home haemodialysis and quality of life
  Edwina Brown, London, United Kingdom
Track 7
TRANSPANTATION AND IMMUNOLOGY

Hot and new in transplantation: selected topics from 2017/18
- Relevant outcomes? The SONG Initiative (Standardized Outcomes In Nephrology)
  Lionel Rostaing, Grenoble, France
- Steroid withdrawal: if and when?
  Maria Haller, Linz, Austria
- Do we still need calcineurin inhibitors in 2018?
  Daniel Abramowicz, Antwerp, Belgium
- Dialysis vintage and outcomes
  Rainer Oberbauer, Vienna, Austria

Humoral immunity (HLA and nonHLA)
- Allorecognition revisited
  Frans H.J. Claas, Leiden, The Netherlands
- Histopathology of humoral alloimmunity
  Jan Becker, Cologne, Germany
- Anti-HLA antibodies - consequences and intervention
  Speaker to be confirmed
- Sensitization to non-HLA epitopes - is this clinical relevant?
  Georg Böhmig, Vienna, Austria

Expanding the donor pool (deceased and live donors) KPD, ABOI, machine perfusion
- How to set up a KPD Program
  Ondrej Viklicky, Prague, Czech Republic
- ABO-I and HLA-I transplantation
  Umberto Maggiore, Parma, Italy
- DCD - Programs
  Speaker to be confirmed
- Marginal kidney donors
  Johan W. De Fijter, Leiden, The Netherlands

Post transplantation diabetes mellitus - relation to obesity and new options/challenges
- Peripheral or central resistance-pre and post transplant factors in PTDM
  Morten Buus Jorgensen, Copenhagen, Denmark
- Insulin secretion and immunosuppression related pathogenesis of PTDM
  Trond Jenssen, Oslo, Norway
- New gastrointestinal hormones for glucose control in obesity and type 2 diabetes - any role in diabetes after transplantation?
  Tina Vilsbøll, Copenhagen, Denmark
- Clinical evolution of PTDM
  Esteban Porrini, La Laguna, Spain

Risk profiling in renal transplant patients
- Metabolic risk profile in renal transplant candidates and in renal transplant patients
  Umberto Maggiore, Parma, Italy
- CV risk in potential renal transplant recipients
  Alan Jardine, Glasgow, UK
- Nocturnal hypertension and renal function loss in renal transplant patients
  George Reusz, Budapest, Hungary

Track 8
HYPERTENSION, DIABETES, VASCULAR DISEASES

Hot topics in hypertension
- Early vascular aging, hypertension and cardiovascular disease
  Stéphane Laurent, Paris, France
- Looking for optimal target blood pressure: implications of the recent trials
  Sverre E. Kjeldsen, Oslo, Norway
- Measuring, analyzing and managing drug adherence
  Michel Burnier, Lausanne, Switzerland
- Potential new targets for antihypertensive therapy
  Krzysztof Narkiewicz, Gdansk, Poland

A new life for sodium in Nephrology
- Sodium and ADPKD progression
  Vicente Torres, Rochester, U.S.A.
- Sodium and the evolution of CKD
  Gerjan Navis, Groningen, The Netherlands
- Proteasuria – the primary mechanism for sodium retention in proteinuric kidney disease
  Ferruh Artunc, Tübingen, Germany

Diabetic nephropathy
- Urine proteome - is there a role in predicting and monitoring diabetic nephropathy
  Peter Rossing, Gentofte, Denmark
- SGLT2 inhibitors, mechanisms behind cardiovascular and renal protection?
  Bo Feldt-Rasmussen, Copenhagen, Denmark
- Incretin based therapies, mechanisms behind cardiovascular and renal protection?
  Johannes F.E. Mann, Munich, Germany
- Ongoing studies in the field
  Speaker to be confirmed
Track 9  
ACUTE KIDNEY INJURY AND INTENSIVE CARE NEPHROLOGY

AKI biomarkers and risk factors  
- Novel biomarkers for prediction/detection of AKI  
  Danilo Fliser, Homburg/Saar, Germany  
- Leukocyte integrin CD11b/CD18  
  Speaker to be confirmed  
- NETs and histones, new players in AKI and AKI-related remote organ injury  
  Hans-Joachim Anders, Munich, Germany  
- Biomarkers for early detection and prognosis of AKI  
  Raymond Vanholder, Ghent, Belgium

AKI in various circumstances  
- AKI in the intensive care unit  
  Michael Joannidis, Innsbruck, Austria  
- AKI after kidney transplantation  
  Alexandre Hertig, Paris, France  
- AKI during disasters  
  Mehmet Sukru Sever, Istanbul, Turkey  
- Consulting the patient with AKI in other clinics: what should be stressed by the nephrologist?  
  Mustafa Arici, Ankara, Turkey

Renal Replacement Therapy in the Intensive Care Unit  
- Renal replacement therapy indications in patients with severe AKI in ICU  
  Julien Maizel, Amiens, France  
- Continuous Renal Replacement Therapy  
  Esteban Poch López de Briñas, Spain  
- Pro RRT Delayed strategy  
  Stéphane Gaudry, Colombes, France  
- Con RRT Delayed strategy  
  Melanie Meersch, Münster, Germany

SPECIAL SESSION

Nephrology Pearls

CME COURSES

IWG -  
Immunonephrology Working Group  
News in the pathogenesis and treatment of immune-mediated renal diseases  
Part 1  
Cyclophosphamide in glomerular disease: is this old drug still to be used or does it have to be dismissed?  
- Introduction and the case of ANCA-associated vasculitis  
  Yasar Caliskan, Istanbul, Turkey  
- The case of lupus nephritis  
  Vladimir Tesar, Prague, Czech Republic  
- The case of membranous nephropathy  
  Jack F.M. Wetzel, Nijmegen, The Netherlands  
- Minimal change disease - Focal glomerulosclerosis  
  Claudio Ponticelli, Milan, Italy  
Part 2  
Renal involvement in rare inflammatory diseases  
- IgG4-related renal disease  
  Giacomo Quattrocchio, Turin, Italy  
- Inflammation in crystal nephropathies  
  Hans-Joachim Anders, Munich, Germany  
- Renal involvement in Familial Mediterranean Fever and Systemic Autoinflammatory Diseases  
  Speaker to be confirmed  
- Renal involvement in scleroderma  
  Speaker to be confirmed

(EURECA-m Working Group - EUropean REnal and CArdiovascular Medicine)  
The challenge of decreasing cardiovascular mortality in CKD  
Part 1  
New therapeutic approaches to improve cardiovascular outcomes in CKD patients  
- Challenges and opportunities of potassium management in CKD and hypertension  
  Patrick Rossignol, Vandoeuvre-Les-Nancy, France  
- Cardio- and nephroprotective properties of SGLT-2 inhibitors: mechanisms and future potential  
  Pantelis A. Sarafidis, Thessaloniki, Greece  
- Iron supplementation in kidney and heart crosstalk: a hope for heart failure treatment  
  Mehmet Kanbay, Istanbul, Turkey  
Part 2  
Focus on prevention: health economy, blood pressure targets and choice of anticoagulation  
- The health-economy of CKD: a plea for more prevention  
  Raymond Vanholder, Ghent, Belgium  
- Hypertension metrics and treatment targets in renal transplantation: an update  
  Francesca Mallamaci, Reggio Calabria, Italy  
- Anticoagulation in CKD patients with atrial fibrillation  
  Gunnar Heine, Homburg/Saar, Germany
Preliminary Scientific Programme

DESCARTES Working Group (Developing Education Science and Care for Renal Transplantation in European States) in collaboration with EKITA, the Organ Expert Section of ESOT on kidney transplantation in Europe
Kidney transplantation: what are the challenges and opportunities ahead?
- The European paired exchange program
  Rainer Oberbauer, Vienna, Austria
- Machine perfusion: does it help to improve outcomes?
  Gabriel C. Oniscu, Edinburgh, United Kingdom
- Minimisation strategies in kidney transplantation: are we making progresses?
  Ondrej Viklicky, Prague, Czech Republic
- FSGS in children
  Licia Peruzzi, Turin, Italy
- The upcoming immunosuppressive drugs
  Klemens Buddde, Berlin, Germany
- Donor specific antibodies before and after transplantation
  Marta Crespo, Barcelona, Spain
- The future of kidney allocation within Eurotransplant
  Uwe Heemann, Munich, Germany

EUDIAL Working Group - European Dialysis
Improving outcomes for the haemodialysis patient
Part 1
Targets of treatment in dialysis patients
- Does achievement of solute clearance targets improve patient outcomes
  Andrew Davenport, London, United Kingdom
- Does achievement of blood pressure targets improve patient outcomes
- Patient perspective of dialysis
Part 2
How to reduce cardiovascular risk?
- Detection, prevention and management of cardiac arrhythmias during dialysis
- Atrial fibrillation: rate or rhythm control, anticoagulation: yes or no
- Does bioimpedance and lung ultrasound guided assessment of target weight improve outcomes
  Carlo Basile, Acquaviva delle Fonti, Italy

ERA-EDTA Registry
- Modeling longitudinal data in survival analysis
- Interaction analyses
- How to validate the predictive value of a biomarker
- Grading evidence
- Impact of epidemiology on public health

European Renal Best Practice

DIABESITY - Working Group
researching on the nephrological impact in relation to diabetes and obesity
Insulin resistance and renal disease
- Insulin resistance: pathogenesis and definitions
  Drazenka Pongrac Barlovic, Ljubljana, Slovenia
- Muscle or liver?
  Morten Buus Jørgensen, Copenhagen, Denmark
- Insulin resistance: cause or consequence of renal disease?
  Mads Hornum, Copenhagen, Denmark
- CKD, dialysis and insulin resistance
  Danilo Fliser, Homburg/Saar, Germany
- Uremia, insulin resistance and beta-cell damage
  Laetitia Koppe, Lyon, France
- Prediabetes and insulin resistance in the waiting list for renal transplantation
  Armando Torres, La Laguna (Tenerife), Spain

Electrolytes and acid-base balance: from physiology to clinic
- Hypokalemia: a clinical perspective
- Hyponatremia and water balance disorders
  Ewoot Hoorn, Rotterdam, The Netherlands
- Seeing the sodium in the patient
  Christoph Kopp, Erlangen, Germany
- Mechanism and regulation of renal magnesium transport: clinical implications
- New paradigms in renal phosphate handling
  Carsten Wagner, Zurich, Switzerland
- Distal tubular acidosis: new findings
  Francesco Trepiccione, Naples, Italy
- Key note talk: The effect of salt on the gut microbiome

EUTOx Working Group - European Uremic Toxin
Uremic toxins: sources and alterations leading to the uremic state
- Systems medicine, molecular mechanisms and pathways involved in CKD
  Harald Mischak, Hannover, Germany
- Molecular modifications of proteins and peptides in CKD
  Joachim Jankowski, Aachen, Germany
- MicroRNA and CKD
- Sulfur amino acid metabolism derangement in uremia
  Alessandra Perna, Naples, Italy
- Understanding the gut-kidney axis in chronic kidney disease
  Rosalinde Masereeuw, Utrecht, The Netherlands
- Uremic toxins and the gut microbiota
  Griet Glorieux, Ghent, Belgium

EuroPD
Integrating dialysis care: getting the best from home therapies
- How do we best help patients make an informed modality choice?
  Hillary Bekker, Leeds, United Kingdom
- What is the best way to deliver assisted peritoneal dialysis?
  Thierry Lobbedez, Caen, France
- How can we best deliver an integrated home therapies dialysis programme?
  James Heaf, Roskilde, Denmark
- Preventing technique failure in PD - what does it mean for the small dialysis programme?
  Speaker to be confirmed

Vascular Access Society (VAS) in collaboration with the Young Nephrologists’ Platform (YNP)

CKB-MBD Working Group
Emerging insights in CKB-MBD
- Position of gastrointestinal sodium-phosphate transporter inhibition
  Ziad Massy, Paris, France
- Novel approaches to treat renal osteodystrophy
  João M. Frazão, Porto, Portugal
- CKB-MBD phenotypes and all-cause mortality
  Marc Vervloet, Amsterdam, The Netherlands
- Novel compounds to regress ectopic calcification
  Mario Cozzolino, Milan, Italy
- Ten years research on FGF23: will it ever enter clinical practice?
  Sandro Mazzaferro, Rome, Italy
- Treatment of CKB-MBD after renal transplantation
  Pieter Evenepoel, Leuven, Belgium

WGIKD - Working Group on Inherited Kidney Diseases
- What’s new in rare kidney diseases?
  Nine Knoers, Utrecht, The Netherlands
- Claudinopathies: a new class of tubulopathies
  Dominik Müller, Berlin, Germany
- Diagnostic and therapeutic management of hypophosphatemic rickets from infancy to adulthood
  Dominique Prié, Paris, France
- Novel therapeutic approaches in primary hyperoxaluria
  Bernd Hoppe, Bonn, Germany
- What’s new in Tuberous Sclerosis Complex?
  Roser Torra, Barcelona, Spain
- Insights from urinary exosome analysis in inherited kidney diseases
  Kirsten Y. Renkema, Utrecht, The Netherlands
- Transitioning rare kidney disease patients from paediatric to adult care
  Speaker to be confirmed

Rheumatology for nephrologists
- Visual diagnosis quiz
  Peter Herzer, Munich, Germany
- Back from the future - steroid free lupus therapy?
  Speaker to be confirmed
- The conundrum of treating gout in patients with CKD
  Jakub Závada, Prague, Czech Republic
- Forms of tubulointerstitial nephritis that need a rheumatology consult
  Manuel Praga, Madrid, Spain

- Bortezomib and bone marrow transplantation - rescue options for severe SLE
  Falk Hiepe, Berlin, Germany
- Can we ever stop immunosuppressive drugs in patients with systemic autoimmune diseases?
  David Jayne, Cambridge, United Kingdom

Onconephrology
Part 1
- CKD in malignancy cause or consequence
  Speaker to be confirmed
- Nephrologic management of renal and urothelial cancer
  Speaker to be confirmed
- Kidney involvement in leukemia and lymphoma
  Jan Kielstein, Braunschweig, Germany
- How to use wisely renal replacement therapy in oncology patients
  Ben Sprangers, Leuven, Belgium

Part 2
- Hypertension in malignancy - comorbidity or complication of the therapy
  Jolanta Malyszko, Bialystok, Poland
- Anemia in cancer patients to use or to avoid ESA and iron
  Petra Tesarova, Prague, Czech Republic
- Acid base disturbances in cancer patients
  Giovambattista Capasso, Naples, Italy
- Electrolytes disorders - common but underappreciated problem in malignancy and its treatment
  Speaker to be confirmed

ERN Working Group - European Renal Nutrition
Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD
- Introduction, overview and rationale for the guidelines
  T. Alp Ikizler, Nashville, U.S.A.
- Methodology and development of the clinical evidence library
  Deepa Handu, Chicago, U.S.A.
- Guideline recommendations for macronutrients
  Denis Fouque, Lyon, France
- Guideline recommendations for micronutrients
  Daniel Teta, Sion, Switzerland
- Guideline recommendations for electrolytes and other nutrients
  Juan Jesus Carrero, Stockholm, Sweden

EULIS, the Section of Urolithiasis of the European Association of Urology
Ethical aspects in dialysis and kidney transplantation in the elderly
- Dialysis - Pro
- Dialysis - Con
- Kidney transplantation - Pro
- Kidney transplantation - Con